GENEREX BIOTECHNOLOGY CORP 4
4 · GENEREX BIOTECHNOLOGY CORP · Filed Mar 10, 2010
Insider Transaction Report
Form 4
FLETCHER MARK
EVP & General Counsel
Transactions
- Award
Common Stock Purchase Option (right to buy)
2009-10-20+470,276→ 470,726 totalExercise: $0.00Exp: 2014-10-26→ Common Stock (470,726 underlying) - Award
Common Stock Purchase Option (right to buy)
2009-10-20+250,000→ 250,000 totalExercise: $0.61Exp: 2014-10-26→ Common Stock (250,000 underlying) - Award
Common Stock Purchase Option (right to buy)
2010-03-08+300,000→ 300,000 totalExercise: $0.64Exp: 2020-03-07→ Common Stock (300,000 underlying) - Disposition to Issuer
Common Stock Purchase Option (right to buy)
2009-10-20−250,000→ 0 totalExercise: $0.61Exp: 2009-12-12→ Common Stock (250,000 underlying) - Disposition to Issuer
Common Stock Purchase Option (right to buy)
2009-10-20−470,726→ 0 totalExercise: $0.00Exp: 2010-04-05→ Common Stock (470,726 underlying)
Footnotes (3)
- [F1]Deemed cancellation of option in connection with deemed grant of replacement option.
- [F2]The reported transaction involved the extension of the term of existing options through October 26, 2014 as previously reported in the issuer's Current Report on Form 8-K filed on October 23, 2009.
- [F3]The option becomes exercisable in three equal installments, with the first installment exercisable as of the date of grant, the second installment exercisable as of August 1, 2010 and the third installment exercisable as of August 1, 2011.